Here are 1-3 brief analogies to describe ENDRA Life Sciences (NDRA):

1. They are like a company making an 'MRI-like upgrade' for standard medical ultrasound machines, allowing them to diagnose specific conditions like fatty liver disease with much greater accuracy and detail, but without the high cost or complexity of a full MRI scan.
2. Think of them as creating the equivalent of a sophisticated 'sonar upgrade' for basic medical ultrasound, allowing it to map and measure internal body characteristics like fat and temperature with much greater precision than ever before.
3. They are like a specialized engineering company that develops sophisticated 'add-on' technology that gives standard medical ultrasound machines the ability to 'see' and precisely measure entirely new types of information, such as tissue temperature or fat content, turning them into far more powerful diagnostic tools.

• Thermo-acoustic enhanced ultrasound technology: This technology improves clinical diagnostic ultrasound capabilities, providing advanced imaging for applications such as nonalcoholic fatty liver disease, temperature monitoring in surgery, vascular imaging, and tissue perfusion.

ENDRA Life Sciences (NDRA) develops specialized technology for enhancing clinical diagnostic ultrasound. Based on the company description, which highlights their development of core technology and a "collaborative research agreement with General Electric Company," ENDRA Life Sciences primarily sells its technology and products to other companies, specifically major medical device manufacturers.

The major customer, or at least the primary identified strategic partner and potential major customer for their integrated technology, is:

• General Electric Company, specifically its healthcare arm, GE HealthCare Technologies Inc. (NYSE: GEHC).

Alexander Tokman – CEO & Director

Richard Jacroux – Chief Financial Officer

Ziad Rouag – Head of Clinical and Regulatory

Idan Steinberg – Head of Engineering

Scott Sober – Head of Operations

The key risks for ENDRA Life Sciences Inc. (NDRA) revolve primarily around its ability to successfully navigate regulatory hurdles, secure adequate funding for its operations, and achieve market acceptance for its innovative technology.

1. Regulatory Approval and Commercialization of TAEUS Technology: The most significant risk for ENDRA Life Sciences is the successful development, regulatory approval, and subsequent commercialization of its proprietary Thermo Acoustic Enhanced Ultrasound (TAEUS) technology, particularly for its liver device. The company is pursuing a De Novo submission with the U.S. Food and Drug Administration (FDA) for its TAEUS Liver device, which involves conducting a statistically powered, multicenter clinical trial. Delays in submitting required regulatory applications, or difficulties in receiving approvals from the FDA or other regulatory agencies, pose a substantial threat to the company's ability to bring its products to market. Furthermore, even upon approval, achieving widespread market acceptance and establishing favorable reimbursement policies for a novel diagnostic technology are significant challenges.
2. Financial Health and Liquidity: ENDRA Life Sciences has a history of recurring net losses and unprofitability, with its Basic EPS indicating severe unprofitability. The company has faced challenges with its balance sheet and liquidity, including receiving a notice of non-compliance from Nasdaq due to insufficient stockholders' equity. While ENDRA has undertaken initiatives, such as private placement financing and a new treasury strategy, to enhance its financial sustainability, the ability to raise additional capital to continue as a going concern remains a critical risk. The company's market capitalization has also seen a significant decline, and low institutional ownership suggests limited confidence from large investors.
3. Competition and Market Adoption: ENDRA operates in the competitive diagnostic imaging market, where established technologies like MRI-PDFF are considered the "gold standard" for liver fat quantification. Although TAEUS aims to provide a lower-cost, point-of-care solution, there is a risk that its technology may not achieve sufficient market acceptance against existing, entrenched diagnostic methods. The company must demonstrate that TAEUS offers superior advantages in terms of cost, accessibility, and clinical efficacy to gain widespread adoption by healthcare providers and patients in the treatment and monitoring of conditions like nonalcoholic fatty liver disease (NAFLD) and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).

ENDRA Life Sciences (symbol: NDRA) develops Thermo-Acoustic Enhanced Ultrasound (TAEUS) technology with several addressable markets:

• Steatotic Liver Disease (SLD), including Non-alcoholic Fatty Liver Disease (NAFLD) and Non-alcoholic Steatohepatitis (NASH) Diagnostics (Liver Fat Quantification): The global non-alcoholic fatty liver disease (NAFLD) diagnostics market was valued at approximately USD 2.41 billion in 2024 and is projected to reach USD 4.76 billion by the end of 2033, growing at a compound annual growth rate (CAGR) of 7.8% from 2025 to 2033. North America represented approximately 38% of this market, valued at USD 0.92 billion, in 2024. The broader global liver disease diagnostics market was valued at USD 35.97 billion in 2023 and is expected to reach USD 64.23 billion by 2032. Within this larger market, the imaging segment held a 32.12% share, and the NAFLD segment held a 24.51% share in 2023. The global non-alcoholic steatohepatitis (NASH) biomarkers market was valued at around USD 1.5 billion in 2024 and is estimated to grow to USD 14.8 billion by 2034, with a CAGR of 25.8% from 2025 to 2034. The company itself states that SLD affects over two billion people globally and more than 100 million people in the United States.

• Temperature Monitoring of Thermoablative Surgery: The global thermal ablation devices market, which represents the context for thermoablative procedures where temperature monitoring is crucial, is estimated to be valued at US$ 5.2 billion in 2026 and is projected to reach US$ 9.3 billion by 2033, with a CAGR of 8.7% between 2026 and 2033.

• Vascular Imaging: The global vascular imaging market size was valued at USD 6.43 billion in 2023 and is expected to grow at a compound annual growth rate (CAGR) of 4.19% from 2024 to 2030, reaching USD 8.52 billion by 2030.

• Tissue Perfusion: The global perfusion imaging market was valued at approximately US$ 2.1 billion in 2022 and is predicted to grow to US$ 8.3 billion by 2032, with a total CAGR of 6.8%. The global contrast-enhanced ultrasound (CEUS) market, which is relevant for assessing blood perfusion in organs, was valued at USD 2.07 billion in 2024 and is projected to reach USD 3.17 billion by 2033, growing at a CAGR of 4.87% during the forecast period (2025-2033).

Here are 3-5 expected drivers of future revenue growth for ENDRA Life Sciences (NDRA) over the next 2-3 years:

1. Strategic Shift and Market Expansion into Metabolic Diseases and GLP-1 Therapy Market: ENDRA Life Sciences is pivoting its strategic focus to develop and deploy its Thermo-Acoustic Enhanced UltraSound (TAEUS) system as a biomarker solution for the early detection and management of metabolic diseases, particularly in patients being treated with GLP-1 drugs. This new target market opportunity is considered larger and more viable than its prior focus on hepatology and radiology. The company plans to target pharmaceutical companies, clinical research organizations for trials, concierge medical practices, bariatric and metabolic clinics, and primary care practices.
2. Regulatory Approval and Commercialization of the TAEUS System for Steatotic Liver Disease (SLD/MASH): A significant driver will be the successful advancement through the FDA regulatory process, specifically the De Novo submission for the TAEUS system to aid in the characterization of liver fat. Achieving FDA approval is crucial for the commercial launch and widespread adoption of their liver fat measurement technology.
3. Expansion of TAEUS Technology into Additional High-Value Clinical Applications: Beyond its initial focus on liver health, ENDRA plans to develop and commercialize TAEUS for other high-value applications, including temperature monitoring for ablation therapies, vascular imaging, and tissue perfusion. This diversification of applications will broaden the addressable market for the TAEUS platform.
4. Adoption of a Subscription-Based Sales Model and Enhanced Market Penetration: To minimize barriers to entry and maximize customer uptake, ENDRA intends to introduce a subscription-based sales model. This, coupled with refining the TAEUS device for improved scalability, ease of use, and cost-effectiveness, aims to enable routine liver fat screening in various healthcare settings, including primary care.

Share Issuance

• In October 2025, ENDRA Life Sciences closed a private placement, generating approximately $4.9 million in gross proceeds from the issuance of 744,340 shares of common stock (or prefunded warrants) and warrants to purchase up to 1,488,680 additional shares.
• The company entered into an at-the-market (ATM) equity agreement in October 2025 with Lucid Capital Markets for up to $1,750,000 in aggregate gross proceeds.
• In December 2025, stockholders approved an amendment to increase the authorized shares of common stock from 20,000,000 to 1,000,000,000.

Inbound Investments

• In October 2025, ENDRA Life Sciences secured approximately $4.9 million in commitments from institutional and cryptocurrency investors through a private placement.
• The private placement in October 2025 has the potential to generate up to an additional $9.5 million in future proceeds if all accompanying warrants are exercised.
• A significant portion of the net proceeds from the October 2025 private placement is intended to establish the company's Digital Asset Treasury (DAT) operations and accumulate cryptocurrency.

Outbound Investments

• ENDRA Life Sciences initiated a strategic initiative in October/November 2025 to enhance balance sheet flexibility by deploying a portion of its capital into an institutional-grade reward-generating program, involving digital assets and cryptocurrency.
• The company purchased 78,863.1 HYPE tokens as part of its digital asset treasury strategy.

Capital Expenditures

• ENDRA Life Sciences reported $0 in capital expenditures in the third quarter of 2025.
• The company's primary focus for resource allocation is the development of its Thermo Acoustic Enhanced Ultrasound (TAEUS®) platform for applications such as liver fat measurement.